More and more companies are encountering added pressures to reduce costs, risks, and time-to-market while maximizing efficiencies. They have converged on a common strategy of outsourcing non-core functions. A trend is developing where companies as small as start-up biotechs to the major pharmaceutical and biopharmaceutical producers are outsourcing their peptide production needs. Whether a company needs research or GMP-grade materials, they are realizing enhanced cost-effectiveness and efficiency by doing so…